Algert Global LLC Purchases 62,802 Shares of Insmed, Inc. $INSM

Algert Global LLC boosted its position in shares of Insmed, Inc. (NASDAQ:INSM) by 76.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 144,726 shares of the biopharmaceutical company’s stock after acquiring an additional 62,802 shares during the period. Algert Global LLC owned 0.07% of Insmed worth $20,842,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of INSM. Savant Capital LLC purchased a new stake in shares of Insmed during the 2nd quarter valued at $205,000. Vise Technologies Inc. acquired a new position in Insmed during the 2nd quarter valued at about $584,000. PNC Financial Services Group Inc. raised its stake in Insmed by 8.8% in the second quarter. PNC Financial Services Group Inc. now owns 11,576 shares of the biopharmaceutical company’s stock valued at $1,165,000 after buying an additional 933 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its stake in Insmed by 83.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 67,903 shares of the biopharmaceutical company’s stock valued at $6,834,000 after buying an additional 30,803 shares during the last quarter. Finally, Creative Planning boosted its holdings in Insmed by 0.6% in the second quarter. Creative Planning now owns 72,176 shares of the biopharmaceutical company’s stock worth $7,264,000 after acquiring an additional 432 shares in the last quarter.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $146.03, for a total transaction of $1,562,374.97. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at $43,982,045.55. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 748 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total transaction of $116,942.32. Following the transaction, the chief financial officer owned 79,758 shares of the company’s stock, valued at $12,469,365.72. This represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 189,651 shares of company stock worth $31,784,545 over the last ninety days. 3.00% of the stock is owned by insiders.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $139.50 on Friday. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The company has a market cap of $30.07 billion, a PE ratio of -21.76 and a beta of 1.13. The company’s 50 day moving average is $155.18 and its 200 day moving average is $165.94.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. The business’s revenue was up 152.6% on a year-over-year basis. On average, sell-side analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on INSM shares. Citigroup restated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Wells Fargo & Company decreased their price objective on shares of Insmed from $234.00 to $208.00 and set an “overweight” rating for the company in a research report on Friday, February 20th. Bank of America set a $203.00 target price on shares of Insmed in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Finally, UBS Group decreased their price target on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a report on Tuesday, January 6th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $207.52.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.